Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. The Group’s main products are contrast agents sold in over 100 countries, both directly and indirectly through branches, joint ventures and license and distribution agreements.
We are looking for a Data Scientist to join our Digital Transformation Office and help turn data into scalable business impact. The Data Scientist designs and deploys machine learning and advanced analytics solutions that create measurable business impact. In this role, you will work across business and technical teams to develop data-driven solutions, improve decision-making, and support key transformation initiatives.
Bachelor's or Master's degree in Data Science, Statistics, Computer Science, Mathematics, Engineering, or a related field.
You will work on high-impact transformation initiatives and help shape the company's AI and analytics journey by building solutions that move from idea to business adoption.
The role is classified at Level C under the National Collective Agreement for the Chemical-Pharmaceutical Industry (CCNL Chimico-Farmaceutico).
The guaranteed minimum base annual gross salary established by the CCNL for the applicable level is € 36.556,24.
The overall compensation will be determined based on the experience, skills, and qualifications of the selected candidate.
Permanent
If you meet the requirements of this opportunity and would like to join an international group working to improve patients' lives, apply now!
At Bracco, we believe in the values of diversity and inclusion. We respect and celebrate the diversity of our people and their experiences, ensuring a fair opportunity for all.

Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,700 employees and annual total consolidated revenues of around 1,7 billion euros, 89% of which from international sales. In the R&D area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors. The Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Bracco offers an extensive and innovative portfolio of products and solutions for all diagnostic modalities completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by it’s American company ACIST. Since its foundation, Bracco has been a socially responsible company in each area of activity - in business as in every other context. Its subsidiary Bracco Imaging is one of the world’s leading companies in the diagnostic imaging field :X-Ray Imaging (including Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound, and Nuclear Medicine. The Company operates in over 110 markets: in North America through Bracco Diagnostics Inc. USA , and with an affiliate in Montreal (Canada); in Europe, with offices in all major countries; in Japan (BRACCO-EISAI). The Company also operates in South America, South Korea and China through its 70% controlled Joint Venture, Bracco Sine Pharmaceutical Corp. Ltd.